Document
1900000020000000false--12-31Q120200001551152Common Stock, par value $0.01 per shareABBV1.000.5720340.0350.160.1620200.0220.010.0140000000004000000000178158260817862409643600000000P5YP3Y204000000620000009710000000.030.210000000060000001500000010000008000000700000020000000302671146309566303 0001551152 2020-01-01 2020-03-31 0001551152 2020-04-30 0001551152 exch:XNYS abbv:Sec1.250SeniorNotesdue2031Member 2020-01-01 2020-03-31 0001551152 exch:XNYS abbv:Sec1.375SeniorNotesDue2024Member 2020-01-01 2020-03-31 0001551152 exch:XNYS abbv:Sec2.125SeniorNotesdue2028Member 2020-01-01 2020-03-31 0001551152 exch:XCHI us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2020-01-01 2020-03-31 0001551152 exch:XNYS us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001551152 2019-01-01 2019-03-31 0001551152 2020-03-31 0001551152 2019-12-31 0001551152 2018-12-31 0001551152 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001551152 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001551152 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001551152 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001551152 us-gaap:TreasuryStockMember 2018-12-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001551152 us-gaap:CommonStockMember 2018-12-31 0001551152 us-gaap:TreasuryStockMember 2019-12-31 0001551152 us-gaap:CommonStockMember 2019-03-31 0001551152 us-gaap:CommonStockMember 2019-12-31 0001551152 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001551152 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001551152 us-gaap:RetainedEarningsMember 2019-03-31 0001551152 us-gaap:RetainedEarningsMember 2018-12-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001551152 us-gaap:CommonStockMember 2020-03-31 0001551152 us-gaap:TreasuryStockMember 2020-03-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001551152 2019-03-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001551152 us-gaap:RetainedEarningsMember 2019-12-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001551152 us-gaap:RetainedEarningsMember 2020-03-31 0001551152 us-gaap:TreasuryStockMember 2019-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001551152 us-gaap:AccountingStandardsUpdate201613Member 2020-03-31 0001551152 srt:ScenarioForecastMember abbv:AllerganplcMember 2020-05-01 2020-05-31 0001551152 srt:ScenarioForecastMember abbv:AllerganplcMember 2020-05-31 0001551152 2019-06-24 0001551152 abbv:JanssenBiotechIncMember us-gaap:CollaborativeArrangementMember 2019-12-31 0001551152 abbv:JanssenBiotechIncMember us-gaap:CollaborativeArrangementMember 2020-03-31 0001551152 abbv:JanssenBiotechIncMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0001551152 us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0001551152 us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0001551152 us-gaap:LicensingAgreementsMember 2020-03-31 0001551152 us-gaap:DevelopedTechnologyRightsMember 2020-03-31 0001551152 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0001551152 us-gaap:LicensingAgreementsMember 2019-12-31 0001551152 srt:WeightedAverageMember abbv:ProbabilityofPaymentforUnachievedMilestonesMember 2020-03-31 0001551152 srt:WeightedAverageMember abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember 2020-03-31 0001551152 srt:WeightedAverageMember abbv:ProjectedYearofPaymentsMember 2020-03-31 0001551152 srt:WeightedAverageMember us-gaap:MeasurementInputDiscountRateMember 2020-03-31 0001551152 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001551152 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001551152 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001551152 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001551152 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-03-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001551152 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-03-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0001551152 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001551152 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001551152 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-31 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 abbv:July2019364DayTermLoanTrancheMember us-gaap:LoansPayableMember 2019-07-12 2019-07-12 0001551152 abbv:AllerganNotesMember us-gaap:SeniorNotesMember 2019-10-25 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 abbv:July2019ThreeYearTermLoanTrancheMember us-gaap:LoansPayableMember 2019-07-12 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 srt:MinimumMember abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember 2020-03-31 0001551152 us-gaap:InterestExpenseMember 2020-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 abbv:AllerganEuroNotesMember us-gaap:SeniorNotesMember 2019-10-25 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2019-01-01 2019-03-31 0001551152 abbv:SeniorNotesIssuedin2019Member us-gaap:SeniorNotesMember 2019-11-01 2019-11-30 0001551152 abbv:May2018TermLoanCreditAgreementMember us-gaap:LoansPayableMember 2019-03-01 2019-03-31 0001551152 abbv:July2019364DayTermLoanTrancheMember us-gaap:LoansPayableMember 2019-07-12 0001551152 abbv:June2019BridgeCreditFacilityMember us-gaap:BridgeLoanMember 2020-01-01 2020-03-31 0001551152 us-gaap:CostOfSalesMember 2020-03-31 0001551152 us-gaap:AccountsReceivableMember 2020-01-01 2020-03-31 0001551152 abbv:July2019FiveYearTermLoanTrancheMember us-gaap:LoansPayableMember 2019-07-12 0001551152 abbv:May2018TermLoanCreditAgreementMember us-gaap:LoansPayableMember 2018-05-01 2018-05-31 0001551152 srt:MaximumMember abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember 2020-03-31 0001551152 abbv:SeniorNotesIssuedin2019Member us-gaap:SeniorNotesMember 2019-11-30 0001551152 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-03-31 0001551152 abbv:ProbabilityofPaymentforEarlyStageIndicationsMember 2020-03-31 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2020-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-12-31 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2020-01-01 2020-03-31 0001551152 abbv:July2019TermLoanCreditAgreementMember us-gaap:LoansPayableMember 2019-07-12 0001551152 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001551152 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-03-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:CommercialPaperMember 2020-03-31 0001551152 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-03-31 0001551152 abbv:ProbabilityofPaymentforApprovedIndicationsMember 2020-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001551152 us-gaap:CommercialPaperMember 2019-03-31 0001551152 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001551152 us-gaap:FairValueInputsLevel1Member 2020-03-31 0001551152 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0001551152 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0001551152 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2019-12-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001551152 us-gaap:CommercialPaperMember 2019-12-31 0001551152 abbv:July2019ThreeYearTermLoanTrancheMember us-gaap:LoansPayableMember 2019-07-12 2019-07-12 0001551152 abbv:July2019FiveYearTermLoanTrancheMember us-gaap:LoansPayableMember 2019-07-12 2019-07-12 0001551152 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2020-03-31 0001551152 srt:MinimumMember abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember 2020-03-31 0001551152 srt:MinimumMember abbv:ProbabilityofPaymentforUnachievedMilestonesMember 2020-03-31 0001551152 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2020-03-31 0001551152 srt:MinimumMember abbv:ProjectedYearofPaymentsMember 2020-03-31 0001551152 srt:MaximumMember abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember 2020-03-31 0001551152 srt:MaximumMember abbv:ProjectedYearofPaymentsMember 2020-03-31 0001551152 srt:MaximumMember abbv:ProbabilityofPaymentforUnachievedMilestonesMember 2020-03-31 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-03-31 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-03-31 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-03-31 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2019-01-01 2019-03-31 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2019-03-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2018-12-31 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2020-01-01 2020-03-31 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2019-12-31 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2020-03-31 0001551152 2019-09-06 2019-09-06 0001551152 2020-02-20 2020-02-20 0001551152 2019-02-21 2019-02-21 0001551152 2019-11-01 2019-11-01 0001551152 2019-06-20 2019-06-20 0001551152 abbv:December2018StockRepurchaseAuthorizationMember 2020-01-01 2020-03-31 0001551152 abbv:RestrictedStockUnitsAndPerformanceSharesMember 2020-03-31 0001551152 us-gaap:EmployeeStockOptionMember 2020-03-31 0001551152 abbv:RestrictedStockUnitsAndPerformanceSharesMember 2020-01-01 2020-03-31 0001551152 abbv:December2018StockRepurchaseAuthorizationMember 2019-01-01 2019-03-31 0001551152 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0001551152 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001551152 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2019-01-01 2019-03-31 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2020-01-01 2020-03-31 0001551152 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0001551152 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001551152 abbv:ElliottAssociatesL.P.Member 2016-06-01 2016-06-30 0001551152 abbv:NovartisVaccinesandDiagnosticsIncandGrifolsWorldwideOperationsLtdMember 2017-03-01 2017-03-31 0001551152 abbv:TestosteroneReplacementTherapyProductsLiabilityLitigationMember 2020-03-31 0001551152 abbv:NiaspanMember 2020-01-01 2020-03-31 0001551152 abbv:AndroGelAntitrustLitigationMember 2020-01-01 2020-03-31 0001551152 abbv:AndroGelAntitrustLitigationMember 2019-09-01 2019-09-30 0001551152 abbv:AndroGelAntitrustLitigationMember 2020-03-31 0001551152 abbv:AndroGelAntitrustLitigationMember 2014-09-01 2014-09-30 0001551152 abbv:DepakoteMember 2020-03-31 0001551152 abbv:AndroGelAntitrustLitigationMember abbv:DisgorgementRemedyMember 2018-06-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SynagisMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:OtherProductsMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:CreonMember country:US 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:ImmunologyMember abbv:RINVOQMember 2020-01-01 2020-03-31 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember country:US 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember 2020-01-01 2020-03-31 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember country:US 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember 2019-01-01 2019-03-31 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember 2019-01-01 2019-03-31 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember country:US 2020-01-01 2020-03-31 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember country:US 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:RINVOQMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:HCVMember abbv:MAVYRETMember country:US 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SynagisMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember country:US 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember 2020-01-01 2020-03-31 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember country:US 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SynthroidMember country:US 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember country:US 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember 2020-01-01 2020-03-31 0001551152 abbv:HCVMember abbv:MAVYRETMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:CreonMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:HCVMember abbv:MAVYRETMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:AndroGelMember country:US 2020-01-01 2020-03-31 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:HCVMember abbv:MAVYRETMember 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SynthroidMember country:US 2020-01-01 2020-03-31 0001551152 abbv:HCVMember abbv:MAVYRETMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember country:US 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:RINVOQMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember 2019-01-01 2019-03-31 0001551152 abbv:HCVMember abbv:VIEKIRAMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:ImmunologyMember abbv:RINVOQMember 2019-01-01 2019-03-31 0001551152 abbv:HCVMember abbv:VIEKIRAMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember 2019-01-01 2019-03-31 0001551152 abbv:OtherProductsMember 2019-01-01 2019-03-31 0001551152 abbv:HCVMember abbv:MAVYRETMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember country:US 2019-01-01 2019-03-31 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember 2019-01-01 2019-03-31 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember country:US 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember 2020-01-01 2020-03-31 0001551152 abbv:ImmunologyMember abbv:RINVOQMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember 2020-01-01 2020-03-31 0001551152 abbv:ImmunologyMember abbv:RINVOQMember country:US 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:AndroGelMember country:US 2019-01-01 2019-03-31 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember country:US 2019-01-01 2019-03-31 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember us-gaap:NonUsMember 2020-01-01 2020-03-31 iso4217:USD iso4217:USD xbrli:shares xbrli:pure abbv:wholesaler xbrli:shares iso4217:GBP iso4217:EUR iso4217:CHF abbv:company abbv:segment abbv:direct_purchaser abbv:investment_fund abbv:lawsuit abbv:claim abbv:class_action abbv:end_payor_purchaser


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
 
(Mark One)
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended March 31, 2020
 
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from                                    to                                   
  
Commission File Number: 001-35565
 
https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage1a38.jpg
AbbVie Inc.
(Exact name of registrant as specified in its charter)
Delaware
 
32-0375147
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. employer identification number) 
 
1 North Waukegan Road
North ChicagoIllinois 60064-6400
Telephone: (847) 932-7900
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.        Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).        Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
Accelerated Filer
Non-Accelerated Filer
Smaller reporting company
 
 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).        Yes No
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, par value $0.01 per share
 
ABBV
 
New York Stock Exchange
 
 
 
 
Chicago Stock Exchange
1.375% Senior Notes due 2024
 
ABBV24
 
New York Stock Exchange
0.750% Senior Notes due 2027
 
ABBV27
 
New York Stock Exchange
2.125% Senior Notes due 2028
 
ABBV28
 
New York Stock Exchange
1.250% Senior Notes due 2031
 
ABBV31
 
New York Stock Exchange
As of April 30, 2020, AbbVie Inc. had 1,476,742,215 shares of common stock at $0.01 par value outstanding.




AbbVie Inc. and Subsidiaries
Table of Contents



2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
1




PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
 
AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings (unaudited)

 
 
Three months ended
March 31,
(in millions, except per share data)
 
2020
 
2019
Net revenues
 
$
8,619

 
$
7,828

 
 
 
 
 
Cost of products sold
 
1,942

 
1,694

Selling, general and administrative
 
1,695

 
1,680

Research and development
 
1,379

 
1,289

Acquired in-process research and development
 

 
155

Total operating costs and expenses
 
5,016

 
4,818

Operating earnings
 
3,603

 
3,010

 
 
 
 
 
Interest expense, net
 
428

 
325

Net foreign exchange loss
 
5

 
6

Other expense, net
 
72

 
135

Earnings before income tax expense
 
3,098

 
2,544

Income tax expense
 
88

 
88

Net earnings
 
$
3,010

 
$
2,456

 
 
 
 
 
Per share data
 
 
 
 
Basic earnings per share
 
$
2.02

 
$
1.65

Diluted earnings per share
 
$
2.02

 
$
1.65

 
 
 
 
 
Weighted-average basic shares outstanding
 
1,481

 
1,480

Weighted-average diluted shares outstanding
 
1,484

 
1,483


The accompanying notes are an integral part of these condensed consolidated financial statements.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
2




AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income (unaudited)

 
 
Three months ended
March 31,
(in millions)
 
2020
 
2019
Net earnings
 
$
3,010

 
$
2,456

 
 
 
 
 
Foreign currency translation adjustments, net of tax expense (benefit) of $(8) for the three months ended March 31, 2020 and $1 for the three months ended March 31, 2019
 
(227
)
 
(103
)
Net investment hedging activities, net of tax expense (benefit) of $20 for the three months ended March 31, 2020 and $19 for the three months ended March 31, 2019
 
72

 
65

Pension and post-employment benefits, net of tax expense (benefit) of $15 for the three months ended March 31, 2020 and $6 for the three months ended March 31, 2019
 
56

 
25

Marketable security activities, net of tax expense (benefit) of $— for the three months ended March 31, 2020 and $— for the three months ended March 31, 2019
 

 
7

Cash flow hedging activities, net of tax expense (benefit) of $(2) for the three months ended March 31, 2020 and $(7) for the three months ended March 31, 2019
 
(2
)
 
(30
)
Other comprehensive loss
 
(101
)
 
(36
)
Comprehensive income
 
$
2,909

 
$
2,420


The accompanying notes are an integral part of these condensed consolidated financial statements.





2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
3




AbbVie Inc. and Subsidiaries
Condensed Consolidated Balance Sheets

(in millions, except share data)
March 31,
2020
 
December 31,
2019
 
(unaudited)
 
 
Assets
 
 
 
Current assets
 
 
 
Cash and equivalents
$
41,142

 
$
39,924

Accounts receivable, net
6,362

 
5,428

Inventories
1,844

 
1,813

Prepaid expenses and other
2,410

 
2,354

Total current assets
51,758

 
49,519

 
 
 
 
Investments
78

 
93

Property and equipment, net
2,961

 
2,962

Intangible assets, net
18,203

 
18,649

Goodwill
15,561

 
15,604

Other assets
2,638

 
2,288

Total assets
$
91,199

 
$
89,115

 
 
 
 
Liabilities and Equity
 
 
 
Current liabilities
 
 
 
Short-term borrowings
$
6

 
$

Current portion of long-term debt and finance lease obligations
3,756

 
3,753

Accounts payable and accrued liabilities
12,709

 
11,832

Total current liabilities
16,471

 
15,585

 
 
 
 
Long-term debt and finance lease obligations
63,284

 
62,975

Deferred income taxes
959

 
1,130

Other long-term liabilities
17,900

 
17,597

 
 
 
 
Commitments and contingencies


 


 
 
 
 
Stockholders’ equity (deficit)
 
 
 
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,786,240,964 shares issued as of March 31, 2020 and 1,781,582,608 as of December 31, 2019
18

 
18

Common stock held in treasury, at cost, 309,566,303 shares as of March 31, 2020 and 302,671,146 as of December 31, 2019
(25,110
)
 
(24,504
)
Additional paid-in capital
15,401

 
15,193

Retained earnings
5,973

 
4,717

Accumulated other comprehensive loss
(3,697
)
 
(3,596
)
Total stockholders’ equity (deficit)
(7,415
)
 
(8,172
)
 
 
 
 
Total liabilities and equity
$
91,199

 
$
89,115


The accompanying notes are an integral part of these condensed consolidated financial statements.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
4




AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Equity (unaudited)

(in millions)
Common shares outstanding
 
Common stock
 
Treasury stock
 
Additional paid-in capital
 
Retained earnings
 
Accumulated other comprehensive loss
 
Total
Balance at December 31, 2018
1,479

 
$
18

 
$
(24,108
)
 
$
14,756

 
$
3,368

 
$
(2,480
)
 
$
(8,446
)
Net earnings

 

 

 

 
2,456

 

 
2,456

Other comprehensive loss, net of tax

 

 

 

 

 
(36
)
 
(36
)
Dividends declared

 

 

 

 
(1,590
)
 

 
(1,590
)
Purchases of treasury stock
(5
)
 

 
(419
)
 

 

 

 
(419
)
Stock-based compensation plans and other
4

 

 
25

 
184

 

 

 
209

Balance at March 31, 2019
1,478

 
$
18

 
$
(24,502
)
 
$
14,940

 
$
4,234

 
$
(2,516
)
 
$
(7,826
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2019
1,479

 
$
18

 
$
(24,504
)
 
$
15,193

 
$
4,717

 
$
(3,596
)
 
$
(8,172
)
Net earnings

 

 

 

 
3,010

 

 
3,010

Other comprehensive loss, net of tax

 

 

 

 

 
(101
)
 
(101
)
Dividends declared

 

 

 

 
(1,754
)
 

 
(1,754
)
Purchases of treasury stock
(7
)
 

 
(643
)
 

 

 

 
(643
)
Stock-based compensation plans and other
5

 

 
37

 
208

 

 

 
245

Balance at March 31, 2020
1,477

 
$
18

 
$
(25,110
)
 
$
15,401

 
$
5,973

 
$
(3,697
)
 
$
(7,415
)

The accompanying notes are an integral part of these condensed consolidated financial statements.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
5




AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (unaudited)

 
Three months ended
March 31,
(in millions) (brackets denote cash outflows)
2020
 
2019
Cash flows from operating activities
 
 
 
Net earnings
$
3,010

 
$
2,456

Adjustments to reconcile net earnings to net cash from operating activities:
 
 
 
Depreciation
115

 
118

Amortization of intangible assets
444

 
385

Change in fair value of contingent consideration liabilities
72

 
169

Stock-based compensation
219

 
189

Upfront costs and milestones related to collaborations
40

 
195

Other, net
1

 
(33
)
Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(1,025
)
 
(316
)
Inventories
(107
)
 
(128
)
Prepaid expenses and other assets
(19
)
 
(112
)
Accounts payable and other liabilities
1,065

 
94

Cash flows from operating activities
3,815

 
3,017

 
 
 
 
Cash flows from investing activities
 
 
 
Acquisitions and investments
(12
)
 
(320
)
Acquisitions of property and equipment
(125
)
 
(107
)
Purchases of investment securities
(13
)
 
(194
)
Sales and maturities of investment securities
26

 
594

Other
(5
)
 

Cash flows from investing activities
(129
)
 
(27
)
 
 
 
 
Cash flows from financing activities
 
 
 
Net change in commercial paper borrowings

 
(200
)
Repayments of other short-term borrowings

 
(3,000
)
Dividends paid
(1,763
)
 
(1,588
)
Purchases of treasury stock
(643
)
 
(620
)
Proceeds from the exercise of stock options
12

 
4

Payments of contingent consideration liabilities
(53
)
 

Other, net
25

 
21

Cash flows from financing activities
(2,422
)
 
(5,383
)
Effect of exchange rate changes on cash and equivalents
(46
)
 
1

Net change in cash and equivalents
1,218

 
(2,392
)
Cash and equivalents, beginning of period
39,924

 
7,289

 
 
 
 
Cash and equivalents, end of period
$
41,142

 
$
4,897


The accompanying notes are an integral part of these condensed consolidated financial statements.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
6




AbbVie Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
Note 1    Basis of Presentation
 

Basis of Historical Presentation
The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2019.
It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
ASU No. 2016-13
In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments - Credit Losses (Topic 326). The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. AbbVie adopted the standard in the first quarter of 2020. The adoption did not have a material impact on the company's consolidated financial statements.
Upon adoption of the standard, accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition, and both current and forecasted economic conditions. The allowance for credit losses was $46 million at March 31, 2020. There were no significant changes in credit loss risk factors that impacted the company's recorded allowance during the three months ended March 31, 2020.
Recent Accounting Pronouncements Not Yet Adopted
ASU No. 2019-12
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740). The standard includes simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard will be effective for AbbVie starting with the first quarter of 2021. AbbVie is currently assessing the impact of this guidance on its consolidated financial statements.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
7




Note 2    Supplemental Financial Information
 
Interest Expense, Net
 
 
Three months ended
March 31,
(in millions)
 
2020
 
2019
Interest expense
 
$
563

 
$
387

Interest income
 
(135
)
 
(62
)
Interest expense, net
 
$
428

 
$
325


Inventories
(in millions)
March 31, 2020
 
December 31, 2019
Finished goods
$
546

 
$
485

Work-in-process
932

 
942

Raw materials
366

 
386

Inventories
$
1,844

 
$
1,813


Property and Equipment
(in millions)
March 31, 2020
 
December 31, 2019
Property and equipment, gross
$
8,250

 
$
8,188

Accumulated depreciation
(5,289
)
 
(5,226
)
Property and equipment, net
$
2,961

 
$
2,962


Depreciation expense was $115 million for the three months ended March 31, 2020 and $118 million for the three months ended March 31, 2019.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
8




Note 3    Earnings Per Share
 
AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.
The following table summarizes the impact of the two-class method:
 
 
Three months ended
March 31,
(in millions, except per share data)
 
2020
 
2019
Basic EPS
 
 
 
 
Net earnings
 
$
3,010

 
$
2,456

Earnings allocated to participating securities
 
14

 
12

Earnings available to common shareholders
 
$
2,996

 
$
2,444

Weighted-average basic shares outstanding
 
1,481

 
1,480

Basic earnings per share
 
$
2.02

 
$
1.65

 
 
 
 
 
Diluted EPS
 
 
 
 
Net earnings
 
$
3,010

 
$
2,456

Earnings allocated to participating securities
 
14

 
12

Earnings available to common shareholders
 
$
2,996

 
$
2,444

Weighted-average shares of common stock outstanding
 
1,481

 
1,480

Effect of dilutive securities
 
3

 
3

Weighted-average diluted shares outstanding
 
1,484

 
1,483

Diluted earnings per share
 
$
2.02

 
$
1.65


Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.
Note 4 Licensing, Acquisitions and Other Arrangements
 

Proposed Acquisition of Allergan plc
On June 25, 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan plc (Allergan) in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019. Under the terms of the transaction agreement, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share. On October 14, 2019, Allergan shareholders approved the proposed transaction.
Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of brands and products primarily focused on key therapeutic areas including aesthetics, eye care, neuroscience, gastroenterology and women's health.
The transaction is subject to customary closing conditions and regulatory approvals. In March 2020, AbbVie and Allergan signed a consent decree agreement with the staff of the U.S. Federal Trade Commission (FTC) regarding the proposed acquisition. Under the terms of the consent decree, the companies have agreed to divest brazikumab, Allergan's IL-23 inhibitor pipeline product, to AstraZeneca and Zenpep, a treatment for exocrine pancreatic insufficiency, to Nestle. Nestle will also acquire Viokace, another pancreatic enzyme preparation, as part of the same transaction. In March 2020, AbbVie and Allergan received final approval from the European Commission to close the pending transaction which was conditional upon the divestiture of brazikumab. In May 2020, AbbVie and Allergan received final approval from the FTC and the Irish High Court to close the transaction. The transaction is expected to close in May 2020.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
9




In anticipation of the proposed acquisition, AbbVie entered into several debt and financing arrangements. See Note 8 for additional information.
Other Licensing & Acquisitions Activity
Cash outflows related to other acquisitions and investments totaled $12 million for the three months ended March 31, 2020 and $320 million for the three months ended March 31, 2019. AbbVie recorded no acquired in-process research and development (IPR&D) charges for the three months ended March 31, 2020 and recorded acquired IPR&D charges of $155 million for the three months ended March 31, 2019.
Note 5 Collaboration with Janssen Biotech, Inc.
 
In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of IMBRUVICA, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to IMBRUVICA, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.
The collaboration provides Janssen with an exclusive license to commercialize IMBRUVICA outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.
In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of IMBRUVICA are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.
Outside the United States, Janssen is responsible for and has exclusive rights to commercialize IMBRUVICA. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.
The following table shows the profit and cost sharing relationship between Janssen and AbbVie:
 
 
Three months ended
March 31,
(in millions)
 
2020
 
2019
United States - Janssen's share of profits (included in cost of products sold)
 
$
450

 
$
386

International - AbbVie's share of profits (included in net revenues)
 
266

 
193

Global - AbbVie's share of other costs (included in respective line items)
 
70

 
72


AbbVie’s receivable from Janssen, included in accounts receivable, net, was $298 million at March 31, 2020 and $235 million at December 31, 2019. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $445 million at March 31, 2020 and $455 million at December 31, 2019.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
10




Note 6    Goodwill and Intangible Assets
 
Goodwill
The following table summarizes the changes in the carrying amount of goodwill:
(in millions)
 
Balance as of December 31, 2019
$
15,604

Foreign currency translation adjustments
(43
)
Balance as of March 31, 2020
$
15,561


The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of March 31, 2020, there were no accumulated goodwill impairment losses.
Intangible Assets, Net
The following table summarizes intangible assets:
 
March 31, 2020
 
December 31, 2019
(in millions)
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
 
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
Definite-lived intangible assets
 
 
 
 
 
 
 
 
 
 
 
Developed product rights
$
19,538

 
$
(6,687
)
 
$
12,851

 
$
19,547

 
$
(6,405
)
 
$
13,142

License agreements
7,798

 
(2,446
)
 
5,352

 
7,798

 
(2,291
)
 
5,507

Total intangible assets, net
$
27,336

 
$
(9,133
)
 
$
18,203

 
$
27,345

 
$
(8,696
)
 
$
18,649


Amortization expense was $444 million for the three months ended March 31, 2020 and $385 million for the three months ended March 31, 2019. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings. No intangible asset impairment charges were recorded for the three months ended March 31, 2020 and 2019.
Note 7    Restructuring Plans
 
AbbVie recorded restructuring charges of $17 million for the three months ended March 31, 2020 and $167 million for the three months ended March 31, 2019.
The following table summarizes the cash activity in the restructuring reserve for the three months ended March 31, 2020:
(in millions)
 
Accrued balance as of December 31, 2019
$
140

Restructuring charges
17

Payments and other adjustments
(38
)
Accrued balance as of March 31, 2020
$
119



2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
11




Note 8    Financial Instruments and Fair Value Measures
 
Risk Management Policy
See Note 11 to the company's Annual Report on Form 10-K for the year ended December 31, 2019 for a summary of AbbVie's risk management policy and use of derivative instruments.
Financial Instruments
Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $842 million at March 31, 2020 and $957 million at December 31, 2019, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of March 31, 2020 are reclassified from accumulated other comprehensive income (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.
In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the proposed acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive income (loss). This gain is reclassified to interest expense, net over the term of the related debt.
In the fourth quarter of 2019, the company entered into interest rate swap contracts with notional amounts totaling $2.3 billion at March 31, 2020 and December 31, 2019. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. The contracts were designated as cash flow hedges and are recorded at fair value. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt.
The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $8.2 billion at March 31, 2020 and $7.1 billion at December 31, 2019.
The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts with notional amounts totaling 971 million, £204 million and CHF62 million as well as 3.6 billion aggregate principal amount of senior Euro notes designated as net investment hedges at March 31, 2020 and December 31, 2019. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.
AbbVie is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $6.3 billion at March 31, 2020 and $10.8 billion at December 31, 2019. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
12




The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:
 
Fair value –
Derivatives in asset position
 
Fair value –
Derivatives in liability position
(in millions)
Balance sheet caption
March 31, 2020
December 31, 2019
 
Balance sheet caption
March 31, 2020
December 31, 2019
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
Designated as cash flow hedges
Prepaid expenses and other
$
35

$
3

 
Accounts payable and accrued liabilities
$

$
14

Designated as cash flow hedges
Other assets
2


 
Other long-term liabilities


Designated as net investment hedges
Prepaid expenses and other
22


 
Accounts payable and accrued liabilities
1

24

Not designated as hedges
Prepaid expenses and other
43

19

 
Accounts payable and accrued liabilities
12

18

Interest rate swap contracts
 
 
 
 
 
 
 
Designated as cash flow hedges
Other assets

3

 
Other long-term liabilities
44


Designated as fair value hedges
Prepaid expenses and other


 
Accounts payable and accrued liabilities

2

Designated as fair value hedges
Other assets
133

28

 
Other long-term liabilities

74

Total derivatives
 
$
235

$
53

 
 
$
57

$
132

While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.
The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):
 
 
Three months ended
March 31,
(in millions)
 
2020
 
2019
Foreign currency forward exchange contracts
 
 
 
 
Designated as cash flow hedges
 
$
49

 
$
3

Designated as net investment hedges
 
40

 

Interest rate swap contracts designated as cash flow hedges
 
(46
)
 


Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $34 million into cost of products sold for foreign currency cash flow hedges, pre-tax losses of $2 million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.
Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax gains of $60 million for the three months ended March 31, 2020 and $84 million for the three months ended March 31, 2019.

2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
13




The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.
 
 
 
Three months ended
March 31,
(in millions)
Statement of earnings caption
 
2020
 
2019
Foreign currency forward exchange contracts
 
 
 
 
 
Designated as cash flow hedges
Cost of products sold
 
$

 
$
40

Designated as net investment hedges
Interest expense, net
 
8

 

Not designated as hedges
Net foreign exchange loss
 
2

 
15

Treasury rate lock agreements designated as cash flow hedges
Interest expense, net
 
6

 

Interest rate swap contracts
 
 
 
 
 
Designated as cash flow hedges
Interest expense, net
 
1

 

Designated as fair value hedges
Interest expense, net
 
360

 
112

Debt designated as hedged item in fair value hedges
Interest expense, net
 
(360
)
 
(112
)

Fair Value Measures
The fair value hierarchy consists of the following three levels:
Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;
Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and
Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability.
The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of March 31, 2020:
 
 
 
Basis of fair value measurement
(in millions)
Total
 
Quoted prices in active markets for
identical assets
(Level 1)
 
Significant other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Assets
 
 
 
 
 
 
 
Cash and equivalents
$
41,142

 
$
1,272

 
$
39,870

 
$

Debt securities
3

 

 
3

 

Interest rate swap contracts
133

 

 
133

 

Foreign currency contracts
102

 

 
102

 

Total assets
$
41,380

 
$
1,272

 
$
40,108

 
$

Liabilities
 
 
 
 
 
 
 
Interest rate swap contracts
$
44

 
$

 
$
44

 
$

Foreign currency contracts
13

 

 
13

 

Contingent consideration
7,359

 

 

 
7,359

Total liabilities
$
7,416

 
$

 
$
57

 
$
7,359


2020 Form 10-Q | https://cdn.kscope.io/baa97208ba3075c26ab92217cabe9f5c-abbvieimage2a15.gif
14




The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2019:
 
 
 
Basis of fair value measurement
(in millions)
Total
 
Quoted prices in active markets for
identical assets
(Level 1)
 
Significant other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Assets
 
 
 
 
 
 
 
Cash and equivalents
$
39,924

 
$
1,542

 
$
38,382

 
$

Debt securities
3

 

 
3

 

Equity securities
24

 
24

 

 

Interest rate swap contracts
31

 

 
31

 

Foreign currency contracts